Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC

ABSTRACT: This study select the diagnosis of postoperative colorectal cancer patients with stage II/III to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process until disease progression or patients died or lost to follow-up. To analyze the difference in efficacy and safety of xelox in 2 weeks and 3 weeks of postoperative adjuvant therapy for colorectal cancer, so as to find a better postoperative adjuvant treatment model.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2275979 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Randomized controlled trial of capecitabine comparing 5-days-on/2-days-off regimen with 2-weeks-on/1-week-off regimen as adjuvant chemotherapy for colorectal cancer(RCT of capecitabine 5-days-on/2-days-off or 2-weeks-on/1-week-off regimen for colorectal cancer)

Project description:Interventions: Capecitabine administered as adjuvant chemotherapy. Group A: capecitabine (2500 mg/m2/day) is taken for five days followed by two days of rest. One course lasts three weeks, and eight courses (24 weeks) are administered. Group B: capecitabine (2500 mg/m2/day) is taken on 14 consecutive days followed by seven days of rest. One course lasts three weeks, and eight courses (24 weeks) are administered.;randomized controlled trial,colorectal cancer, adjuvant chemotherapy Primary outcome(s): Treatment completion rate, feasibility Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

| 2615345 | ecrin-mdr-crc

XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).

Project description: Not available

| S-EPMC9017757 | biostudies-literature

Hepatectomy + XELOX for Liver Metastasis of Colorectal Cancer.

Project description:Interventions: adjuvant Xeloda followed by XELOX total 5 course after curative resection of liver metastasis from colorectal carcinoma. Primary outcome(s): completion rate of adjuvant chemotherapy Study Design: Single arm Non-randomized

| 2626535 | ecrin-mdr-crc

Efficacy of orally administered LEM extract on host QOL and side effect in colorectal cancer patients treated with adjuvant chemotherapy (XELOX).

Project description:Interventions: Orally administered LEM of 1,800mg/day for 6 months during adjuvant chemotherapy (XELOX) Orally administered placebo for 6 months during adjuvant chemotherapy (XELOX) Primary outcome(s): Improvement of QOL with LEM in patients undergoing adjuvant chemotherapy Study Design: Parallel Randomized

| 2642437 | ecrin-mdr-crc

Expression data from 13 week human fetal scalp epidermis sorted for expression of alpha 6 integrin and CD133

Project description:CD133 is expressed by a subpopulation of human fetal hair follicle placode cells during early hair development. Its expression, which is gradually lost as the placode matures, correlates with early morphogenesis. We used microarrays to analyze differences in gene expression between alpha-6 integrin+CD133+ basal cells and other human fetal epidermal populations to provide candidates defining this unique hair follicle placode subpopulation.

2014-07-01 | GSE58393 | GEO

Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

Project description:This study makes an observation over the objective response rate of Apatinib and XELOX combination regimen in the first-line treatment of metastatic colorectal cancer. All the participants will receive the treatment of Apatinib and XELOX combination regimen.

| 2219525 | ecrin-mdr-crc

A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the patient with advanced colorectal cancer

Project description:Interventions: Adjuvant chemotherapy with capecitabine plus oxaliplatin Primary outcome(s): Patients ratio with completion of adjuvant XELOX therapy Study Design: Single arm Non-randomized

| 2618630 | ecrin-mdr-crc

Gene expression profiling of biopsy and resection samples from the DEBIOC phase 1 trial of oxaliplatin and capecitabine +/- AZD8931 in oesophageal cancer

Project description:The Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC) trial reported an acceptable safety profile for neoadjuvant Oxaliplatin and Capecitabine (Xelox) +/- AZD8931 in oesophageal adenocarcinoma (OAC) but limited efficacy. We evaluated the impact of neoadjuvant Xelox +/-AZD8931 on biological pathways using a unique software-driven solution. Transcriptomic profiles from 25 pre-treatment FFPE OAC biopsies and 17 matched resection specimens, treated with Xelox+AZD8931 (n=16) and Xelox alone (n=9), were analysed using the Almac claraT total mRNA report. Tumour Infiltrating Lymphocytes (TILs) were assessed digitally using QuPath software. Hierarchical clustering identified three molecular subgroups classified by activation of innate immune signalling. The Immune High subgroup was associated with HER2 positivity, increased pathological response and a marked reduction in immune signalling and TILs following neoadjuvant therapy. The Immune Low cluster was pre-dominantly HER2/EGFR negative and EGFR positivity was associated with the Immune Mixed subgroup. Neoadjuvant therapy induced angiogenesis and EMT signalling and a reduction in DNA repair signatures with AZD8931 also promoting an immunosuppressive microenvironment. OAC may be subdivided into three immune-related subgroups which undergo modulation in response to neoadjuvant therapy with marked suppression of the immune microenvironment in HER2 positive/Immune High tumours.

2024-09-01 | E-MTAB-13741 | biostudies-arrayexpress

Expression data from 13 week human fetal scalp epidermis sorted for expression of alpha 6 integrin and CD133

2014-07-01 | E-GEOD-58393 | biostudies-arrayexpress

RNA Seq of TFH cells in Th1 vaccine regimen

Project description:Generating durable humoral immunity through vaccination depends upon effective interaction of follicular helper T cells (Tfh) with germinal center (GC) B cells. Th1 polarization of Tfh cells is an important process shaping the success of Tfh-GC B cell interactions by influencing co-stimulatory and cytokine-dependent Tfh help to B cells. However, the question remains whether adjuvant-dependent modulation of Tfh cells enhances HIV-1 vaccine-induced anti-Envelope (Env) antibody responses. We investigated whether an HIV-1 vaccine platform designed to increase the number of Th1-polarized Tfh cells enhances the magnitude and quality of anti-Env antibodies. Utilizing a novel interferon-induced protein (IP)-10-adjuvanted HIV-1 DNA prime, followed by an MPLA+QS-21-adjuvanted Env protein boost in macaques (DIP-10 PALFQ), we observed higher anti-Env serum IgG titers with greater cross-clade reactivity, specificity to V1V2, and effector functions when compared to macaques primed with DNA lacking IP-10 and boosted with MPLA+alum-adjuvanted Env protein (DPALFA) The DIP-10 PALFQ vaccine regimen elicited higher anti-Env IgG1 and lower IgG4 antibodies in serum, showing for the first time that adjuvants can dramatically impact the IgG subclass profile in macaques. The DIP-10 PALFQ regimen also increased vaginal and rectal IgA antibodies to a greater extent. Within lymph nodes, we observed augmented GC B cell responses and promotion of Th1 gene expression profiles in GC Tfh cells. The frequency of GC Tfh cells correlated with both the magnitude and avidity of anti-Env serum IgG. Together, these data suggest that adjuvant-induced stimulation of Th1-Tfh cells is an effective strategy for enhancing the magnitude and quality of anti-Env antibody response.

2019-12-10 | GSE141707 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data